Tacrolimus is a 23-membered macrolide lactone with potent immunosuppressive activity that is effective in the prophylaxis of organ rejection following kidney, heart and liver transplantation. Tacrolimus also exerts a variety of actions on bone metabolism. The aim of the present study was to evaluate the effects of different concentrations of tacrolimus on the morphology and viability of human stem cells derived from the gingiva. Gingival-derived stem cells were grown in the presence of tacrolimus at final concentrations ranging from 0.001 to 100 µg/ml. The morphology of the cells was viewed under an inverted microscope and the cell viability was analyzed using Cell Counting kit-8 (CCK-8) on days 1, 3, 5 and 7. Alizarin Red S staining was used to assess mineralization of treated cells. The control group showed spindle-shaped, fibroblast-like morphology and the shapes of the cells in 0.001, 0.01, 0.1, 1 and 10 µg/ml tacrolimus were similar to those of the control group. All groups except the 100 µg/ml group showed increased cell proliferation over time. Cultures grown in the presence of tacrolimus at 0.001, 0.01, 0.1, 1 and 10 µg/ml were not identified to be significantly different compared with the control at days 1, 3 and 5 using the CCK-8 assays. Increased mineralized deposits were noted with increased incubation time. Treatment with tacrolimus from 0.001 to 1 µg/ml led to an increase in mineralization compared with the control group. Within the limits of this study, tacrolimus at the tested concentrations (ranging from 0.001 to 10 µg/ml) did not result in differences in the viability of stem cells derived from gingiva; however it did enhance osteogenic differentiation of the stem cells.
Mesenchymal stem cells (MSCs) are multipotent progenitor cells that have the capacity for self-renewal and differentiation into osteocytes, adipocytes and other cells (1). MSCs have been used in preclinical models for tissue engineering of bone, cartilage, muscle, marrow stroma, tendon, fat and other connective tissues (2–4). In addition, MSCs secrete a broad spectrum of bioactive macromolecules that are immunomodulatory and serve to structure regenerative microenvironments in fields of tissue injury (5). Human mesenchymal stem cells have previously been isolated and characterized from the gingiva, and gingiva-derived stem cells have been applied for tissue engineering purposes (6). Moreover, stem cells may be obtained intraorally, and gingiva is a readily accessible tissue source with a relatively high quantity of obtainable tissue (7).
Tacrolimus is a 23-member macrolide lactone (molecular weight, 803.5 Da) with potent immunosuppressive activity that is effective in the prophylaxis of organ rejection following liver, heart, kidney and small bowel transplantation (8). Tacrolimus has a narrow therapeutic window (9) and it is important to choose the right dose (10). Clinically, the doses of tacrolimus administered following kidney, heart and liver transplantation are 0.15–0.3, 0.05–0.075 and 0.10–0.2 mg/kg/day, respectively (11–14). In addition, whole blood tacrolimus concentrations were observed to be 10–15 ng/ml during months 1–3 and 5–12 ng/ml during months 4–12 with the initial tacrolimus dose of 0.15–0.2 mg/kg/day (14,15).
Tacrolimus has been shown to exert a variety of actions on bone metabolism (16). It was reported that tacrolimus causes bone loss when administered systemically (17,18). However, other studies have shown that tacrolimus promotes osteogenic differentiation (19,20). Conversely, another study demonstrated that tacrolimus was not associated with osteogenic differentiation of human heart-derived MSCs (21).
Limited information is currently available regarding the effects of tacrolimus on dental tissue, and none is available on its effects on human mesenchymal stem cells derived from the gingiva. The aim of the present study was to evaluate the effects of a broad range of concentrations of tacrolimus on the morphology and viability of human stem cells derived from the gingiva.
Materials and methodsIsolation and culture of stem cells derived from the gingiva
Healthy gingival tissue samples were collected from healthy patients (mean age, 51.8±18.1 years; 2 male and 2 female) and this study was reviewed and approved by the Institutional Review Board of Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea (Seoul, Korea; approval no. KC11SISI0348); informed consent was obtained from all patients. The resected gingival tissues were immediately placed in sterile phosphate-buffered saline (PBS; Welgene Inc., Daegu, Korea) with 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 4°C. The gingival tissue was de-epithelialized, minced into 1–2 mm2 fragments, and digested in 0.2 µm filtered α-Minumum Essential Medium (MEM; HyClone; GE Healthcare Life Sciences, Chalfont, UK) with collagenase IV (Sigma-Aldrich). The cells were incubated at 37°C in a humidified incubator with 5% CO2 and 95% O2. After 24 h, the non-adherent cells were washed with PBS, and adherent cell were administered fresh medium and replaced every 2–3 days. A previous report demonstrated that these cells showed colony-forming abilities, plastic adherence, and multilineage differentiation (osteogenic, adipogenic, chondrogenic) potency (22). The cells expressed CD44, CD73, CD90, and CD105, but did not express CD14, CD45, CD34, and CD19 in flow cytometry (22).
Evaluation of cellular morphology
The cells were plated at a density of 2.0×103 cells/well in 96-well plates. The cells were incubated in α-MEM containing 15% fetal bovine serum (Gibco; Thermo Fisher Scientific Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin in the presence of tacrolimus at final concentrations ranging of 0 (control), 0.001, 0.01, 0.1, 1, 10 and 100 µg/ml. Tacrolimus was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and filter-sterilized. Equal quantities of DMSO were added to each culture sample to offset the influence of this dissolving vehicle. The morphology of the cells was viewed under an inverted microscope (Leica DM IRM, Leica Microsystems, Wetzlar, Germany) on days 1, 3, 5 and 7. The images were saved as JPEGs.
Determination of cell viability
The cell viability analysis was performed on days 1, 3, 5 and 7. 2-(2-methoxy-4-nitrophe nyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H tetrazolium, monosodium salt (WST-8 from Cell Counting kit-8; Dojindo, Tokyo, Japan) was added to the culture and the cells were incubated for 3 h at 37°C. Viable cells were identified using the CCK-8 assay, which relies on the ability of mitochondrial dehydrogenases to oxidize WST-8 to a formazan product. The spectrophotometric absorbance at 450 nm was measured using a microplate reader (BioTek Instruments Inc., Winooski, VT, USA). The tests were performed in triplicate.
Alizarin Red S staining
Cell cultures obtained on days 5 and 7 were washed twice with PBS, fixed with 70% ethanol and rinsed twice with deionized water. Cultures were stained with Alizarin Red S (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and evaluated with a microscope (Leica DM IRB; Leica Microsystems). To remove non-specifically bound stain, cultures were washed three times with deionized water and once with PBS for 15 min at ambient temperature. Bound dye was solubilized in 10 mM sodium phosphate containing 10% cetylpyridinium chloride (Sigma-Aldrich) and quantified spectrophotometrically at 560 nm (PowerWave XS2; BioTek Instruments, Inc., Winooski, VT, USA).
Statistical analysis
The data are presented as the mean ± standard deviation of the experiments. A one-way analysis of variance with post-hoc test was performed to determine the differences between the groups using a commercially available program (SPSS 12 for Windows, SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
ResultsEvaluation of cell morphology
The control group showed normal fibroblast morphology on day 1 (Fig. 1). The shapes of the cells treated with 0.001, 0.01, 0.1, 1 and 10 µg/ml tacrolimus were similar to those of the control group. However, the 100 µg/ml group was markedly different when compared with the control group. The shapes of the cells in the 100 µg/ml group were rounder, and fewer cells were present. The morphology of the cells on day 3 is shown in Fig. 2. An increased number of cells were observed in each group and the shapes of the cells in the tested groups were similar to those in the control group. The results for cells on days 5 and 7 are shown in Figs. 3 and 4, respectively. Noticeable differences were observed in the 100 µg/ml group.
Cellular viability
The CCK-8 results demonstrated cellular viability on days 1, 3, 5 and 7 are shown in Fig. 5. All groups except the 10 and 100 µg/ml group showed relatively increased cell proliferation over time. The cultures grown in the presence of tacrolimus at 0.001, 0.01, 0.1, 1 and 10 µg/ml did not show any statistically significant differences compared with the control at days 1, 3 and 5 using the CCK-8 assays (P>0.05). However, growth in the presence of tacrolimus at a concentration of 100 µg/ml resulted in decreases in the CCK-8 values at days 3, 5 and 7 (P<0.05).
Mineralization assay
Mineralized extracellular deposits were minimally observed after Alizarin Red S staining on day 5 (Fig. 6). Increased mineralized deposits were noted on day 7 (Fig. 7). The quantitative results regarding bound dye on days 5 and 7 are shown in Fig. 8. The cultures grown in the presence of 0.001, 0.01, 0.1 and 1 µg/ml tacrolimus exhibited increased mineralized deposits compared with the control on day 5. The relative values of the mineralization at 0.001, 0.01, 0.1 and 1 µg/ml of tacrolimus were 110.9±10.7%, 102.1±8.4%, 106.5±8.0%, and 111.8±6.7%, respectively when the result of the control group on day 5 was considered to be 100% (100.0±9.1%). A significant decrease in mineralization was observed in the 100 µg/ml group on day 5 in comparison with the control group (P<0.05). The results for day 7 showed that treatment with tacrolimus at concentrations 0.001–1 µg/ml led to increase mineralized deposits compared with the control group. The relative value of the mineralization at 0.001, 0.01, 0.1 and 1 µg/ml of tacrolimus were 118.0±11.2, 123.6±12.3, 118.3±4.5 and 104.4±5.9%, respectively, when the result of the control group on day 7 was considered 100% (100.0±5.4%). A statistically significant decrease was observed in the 100 µg/ml group on day 7 in comparison with the control group (P<0.05).
Discussion
Immunosuppressants have provided great improvement in organ transplantation by suppressing the rejection of allografts; this has increased the survival rate of organ transplant patients (23). Tacrolimus (FK506) is a widely-used, well-known immunosuppressant used following kidney or heart transplantation, and has been recognized as effective in promoting the growth of bone grafts (24). The present study was performed in order to investigate the effects of tacrolimus on proliferation and osteoblastic differentiation of mesenchymal stem cells in vitro.
This study determined the effects of tacrolimus on the morphology, cell viability and mineralization following treatment with 0.001–100 µg/ml tacrolimus. The cells exposed to tacrolimus at concentrations of 0.001–10 µg/ml exhibited a similar fibroblastic spindle shape. Short-term application of tacrolimus did not result in morphologic changes at final concentrations ranging from 0.001 to 10 µg/ml.
Cellular viability was determined using a CCK-8 assay, which is based on mitochondrial enzyme reduction of the WST-8 and spectrophotometric quantification of the water-soluble formazan dye generated (25). This study showed that tacrolimus at the tested concentrations was not identified to exhibit a significant effect on the viability of stem cells derived from the gingiva at final concentrations ranging from 0.001 to 10 µg/ml. However, tacrolimus at 100 µg/ml decreased cell viability on days 3, 5 and 7.
Osteogenic differentiation can be evaluated by Alizarin red S staining (26). The presence of calcium in cellular deposits was confirmed by Alizarin Red S staining with cetylpyridinium chloride for quantification (27). Tacrolimus at 0.001, 0.01 and 1 µg/ml resulted in the highest degree of mineralized nodule formation on day 7. A previous study showed that tacrolimus at 0.04 and 0.4 µg/ml enhanced osteoblastic differentiation of rat mesenchymal stem cells (20). Co-stimulation with tacrolimus (1.0 µg/ml) and bone morphogenetic protein-9 (100 ng/ml) induced marked osteoblastic differentiation of dedifferentiated fat cells, which were isolated from mature adipocytes using the ceiling culture method and exhibit similar characteristics to mesenchymal stem cells (28). In the present study, the highest differentiation was achieved at 0.01 µg/ml; however, a previous study demonstrated that remarkable osteoblast differentiation was achieved at 1.0 µg/ml (20). The differences may be explained by the different type and stage of the cells, the culturing time period and the culture system (29,30).
A previous study demonstrated that tacrolimus promoted the early stage of osteoinduction (24). The mechanism underlying osteogenic differentiation has not yet been fully elucidated; however, it has been suggested that the osteogenic effect of tacrolimus may involve bone morphogenetic protein signaling (16). A previous report suggested that tacrolimus promoted osteogenic differentiation by activating BMP receptors through interacting with FK506-binding protein 12 (16). Tacrolimus enhanced the positive effects of bone morphogenetic proteins on alikaline phosphatase activity and osteocalcin in mRNA (19). The effects of the combination treatment with bone morphogenetic protein and tacrolimus acted in a dose- and time-dependent manner (19).
In conclusion, the present study demonstrated that treatment with tacrolimus at the tested concentrations ranging from 0.001 to 10 µg/ml did not result in significant changes in the viability of stem cells derived from gingiva, but increased osteogenic differentiation of the stem cells. Further studies related to this phenomenon in an in vivo model are necessary in order to ascertain greater understanding.
Acknowledgments
This study was supported by the 2015 Yeungnam University, Basic Science Research Program (grant nos. 2014R1A1A1002536 and 2015R1A2A2A04005616) and the Medical Research Center Program (grant no. 2015R1A5A2009124) through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning.
ReferencesBeyer NardiNda Silva MeirellesLMesenchymal stem cells: Isolation, in vitro expansion and characterizationHandb Exp Pharmacol:249282200610.1007/3-540-31265-X_11ChenWCPéaultBHuardJRegenerative translation of human blood-vessel-derived MSC precursorsStem Cells Int2015375187201510.1155/2015/375187262733044529976DengSHuangRWangJZhangSChenZWuSJiangYPengQCaiXLinYMiscellaneous animal models accelerate the application of mesenchymal stem cells for cartilage regenerationCurr Stem Cell Res Ther9223233201410.2174/1574888X0966614021320133124524791Landa-SolísCGranados-MontielJOlivos-MezaAOrtega-SánchezCCruz-LeminiMHernández-FloresCChang-GonzálezMEGarcíaRGOlivos-DíazBVelasquillo-MartínezMCCryopreserved CD90+ cells obtained from mobilized peripheral blood in sheep: a new source of mesenchymal stem cells for preclinical applicationsCell Tissue BankJuly292015Epub ahead of printCaplanAIAdult mesenchymal stem cells for tissue engineering versus regenerative medicineJ Cell Physiol213341347200710.1002/jcp.2120017620285LeeSIYeoSIKimBBKoYParkJBFormation of size-controllable spheroids using gingiva-derived stem cells and concave microwells: Morphology and viability testsBiomed Rep4971012016268703434726850JeongSHLeeJEKimBBKoYParkJBEvaluation of the effects of Cimicifugae Rhizoma on the morphology and viability of mesenchymal stem cellsExp Ther Med106296342015266223664509119TamuraSOhikeAIbukiRAmidonGLYamashitaSTacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in ratsJ Pharm Sci91719729200210.1002/jps.1004111920757ScholtenEMCremersSCSchoemakerRCRowshaniATvan KanEJden HartighJPaulLCde FijterJWAUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipientsKidney Int6724402447200510.1111/j.1523-1755.2005.00352.x15882290FelipeCRGarciaCMoreiraSOlsenNSilvaHTPestanaOMChoosing the right dose of new immunossuppressive drugs for new populations: Importance of pharmacokinetic studiesTransplant Proc3310951096200110.1016/S0041-1345(00)02432-511267207van HooffJPBootsJMvan DuijnhovenEMChristiaansMHDosing and management guidelines for tacrolimus in renal transplant patientsTransplant Proc3154S57S199910.1016/S0041-1345(99)00796-410576046TaylorDOBarrMLRadovancevicBRenlundDGMentzerRMJrSmartFWTolmanDEFrazierOHYoungJBVanVeldhuisenPA randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimusJ Heart Lung Transplant18336345199910.1016/S1053-2498(98)00060-610226898BusuttilRWKlintmalmGBLakeJRMillerCMPoraykoMGeneral guidelines for the use of tacrolimus in adult liver transplant patientsTransplantation61845847199610.1097/00007890-199603150-000328607197StaatzCETettSEClinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantationClin Pharmacokinet43623653200410.2165/00003088-200443100-0000115244495LaskowDANeylanJFIIIShapiroRSPirschJDVergne-MariniPJTomlanovichSJThe role of tacrolimus in adult kidney transplantation: A reviewClin Transplant1248950319989850440KugimiyaFYanoFOhbaSIgawaKNakamuraKKawaguchiHChungUIMechanism of osteogenic induction by FK506 via BMP/Smad pathwaysBiochem Biophys Res Commun338872879200510.1016/j.bbrc.2005.10.02416246307ParkKMHayJELeeSGLeeYJWiesnerRHPoraykoMKKromRABone loss after orthotopic liver transplantation: FK 506 versus cyclosporineTransplant Proc281738174019968658863StempfleHUWernerCEchtlerSAssumTMeiserBAngermannCETheisenKGärtnerRRapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppressionTransplant Proc3011321133199810.1016/S0041-1345(98)00181-X9636459TangLEbaraSKawasakiSWakabayashiSNikaidoTTakaokaKFK506 enhanced osteoblastic differentiation in mesenchymal cellsCell Biol Int267584200210.1006/cbir.2001.081211779223ByunYKKimKHKimSHKimYSKooKTKimTISeolYJKuYRhyuICLeeYMEffects of immunosuppressants, FK506 and cyclosporin A, on the osteogenic differentiation of rat mesenchymal stem cellsJ Periodontal Implant Sci427380201210.5051/jpis.2012.42.3.73228030083394998HoogduijnMJCropMJKorevaarSSPeetersAMEijkenMMaatLPBalkAHWeimarWBaanCCSusceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid and rapamycinTransplantation8612831291200810.1097/TP.0b013e31818aa53619005411JinSHLeeJEYunJHKimIKoYParkJBIsolation and characterization of human mesenchymal stem cells from gingival connective tissueJ Periodontal Res50461467201510.1111/jre.12228LechlerRISykesMThomsonAWTurkaLAOrgan transplantation - how much of the promise has been realized?Nat Med11605613200510.1038/nm125115937473KaiharaSBesshoKOkuboYSonobeJKusumotoKOgawaYIizukaTEffect of FK506 on osteoinduction by recombinant human bone morphogenetic protein-2Life Sci72247256200210.1016/S0024-3205(02)02244-012427484UtheimTPRaederSUtheimØACaiYRoaldBDrolsumLLybergTNicolaissenBA novel method for preserving cultured limbal epithelial cellsBr J Ophthalmol91797800200710.1136/bjo.2006.103218BangSMMoonHJKwonYDYooJYPaeAKwonIKOsteoblastic and osteoclastic differentiation on SLA and hydrophilic modified SLA titanium surfacesClin Oral Implants Res25831837201410.1111/clr.12146WangBBiMZhuZWuLWangJEffects of the antihypertensive drug benidipine on osteoblast function in vitroExp Ther Med76496532014245202613919856NakamuraTShinoharaYMomozakiSYoshimotoTNoguchiKCo-stimulation with bone morphogenetic protein-9 and FK506 induces remarkable osteoblastic differentiation in rat dedifferentiated fat cellsBiochem Biophys Res Commun440289294201310.1016/j.bbrc.2013.09.07324064349QuarlesLDYohayDALeverLWCatonRWenstrupRJDistinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: An in vitro model of osteoblast developmentJ Bone Miner Res7683692199210.1002/jbmr.56500706131414487ParkJBZhangHLinCYChungCPByunYParkYSYangVCSimvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors αJ Surg Res174278283201210.1016/j.jss.2010.12.029
Evaluation of cell morphology on day 1 using inverted microscopy following treatment with tacrolimus of different concentrations. (A) Control, (B) 0.001 µg/ml group, (C) 0.01 µg/ml group, (D) 0.1 µg/ml group, (E) 1 µg/ml group, (F) 10 µg/ml group and (G) 100 µg/ml group.
Cell morphology on day 3 using inverted microscopy following treatment with tacrolimus of different concentrations. (A) Control, (B) 0.001 µg/ml group, (C) 0.01 µg/ml group, (D) 0.1 µg/ml group, (E) 1 µg/ml group, (F) 10 µg/ml group and (G) 100 µg/ml group.
Cell morphology on day 5 using inverted microscopy following treatment with tacrolimus of different concentrations. (A) Control, (B) 0.001 µg/ml group, (C) 0.01 µg/ml group, (D) 0.1 µg/ml group, (E) 1 µg/ml group, (F) 10 µg/ml group, (G) 100 µg/ml group.
Cell morphology on day 7 using inverted microscopy following treatment with tacrolimus of different concentrations. (A) Control, (B) 0.001 µg/ml group, (C) 0.01 µg/ml group, (D) 0.1 µg/ml group, (E) 1 µg/ml group, (F) 10 µg/ml group and (G) 100 µg/ml group.
Cellular viability using cell counting kit-8 assay on days 1, 3, 5 and 7 following treatment with different concentrations of tacrolimus. *P<0.05 compared with the control group at day 3. **P<0.05, compared with the control group at day 5. #P<0.05 compared with the control group at day 7.
Results of Alizarin Red S staining on day 5 following treatment with different concentrations of tacrolimus. (A) Control, (B) 0.001 µg/ml group, (C) 0.01 µg/ml group, (D) 0.1 µg/ml group, (E) 1 µg/ml group, (F) 10 µg/ml group, (G) 100 µg/ml group.
Results of Alizarin Red S staining on day 7 following treatment with different concentrations of tacrolimus. (A) Control, (B) 0.001 µg/ml group, (C) 0.01 µg/ml group, (D) 0.1 µg/ml group, (E) 1 µg/ml group, (F) 10 µg/ml group, (G) 100 µg/ml group.
Quantitative results of mineralization assay on days 5 and 7. *P<0.05 compared with the control group at day 5. **P<0.05 compared with the control group at day 7.